Insulinoresistance in patients with mastopathy and its effect on the clinical course of mastopathy
Автор: Yuldashev Otabek Sabirovich, Karimova Mukima Mamasadikovna, Boboeva Dinora Shokirzhanovna, Faizullaev Bakhrom Rustamovich
Журнал: Re-health journal.
Рубрика: Диабетология
Статья в выпуске: 4 (20), 2023 года.
Бесплатный доступ
Mastopathy is the most common disease in women, accounting for 90% of the flow of diseases in mammology. The etiology of fibrocystic mastopathy has not been fully elucidated, but many studied risk factors include endocrine disorders, particularly insulin resistance and thyroid disease. Objective: To study the incidence of insulin resistance in patients with fibrocystic mastopathy and the effect of metformin on the clinical course of mastopathy. Research sources and methods. The source of the study was 71 women of childbearing age (18-49 years) who were diagnosed with fibrous cystic mastopathy on the basis of the Urgench branch of the Tashkent Medical Academy. Results. There is a strong correlation between decreased insulin resistance and the clinical course of mastopathy. There is a reliable correlation between metformin intake and UTT conclusion BIRADS category reduction in women with insulinresistant mastopathy.
Mastopathy, mastalgia, insulin resistance, metformin
Короткий адрес: https://sciup.org/14130688
IDR: 14130688
Список литературы Insulinoresistance in patients with mastopathy and its effect on the clinical course of mastopathy
- Sadaf Alipour, Hadith Rastad Metformin in the management of fibrocystic breast disease: a placebo-controlled randomized clinical tria. DARU Journal of Pharmaceutical Sciences (2021) 29:389—396.
- Sadaf Alipour, Mahboubeh Abedi. Metformin as a new option in the medical management of breast fibroadenoma; a randomized clinical trial BMC Endocrine Disorders (2021) 21:169 https://doi.org/10.1186/s12902-021-00824-4 .
- Kats I.P., Pavlova E.A., Ordiyants I.M. The role of genetic factors and immune disorders in the development of benign diseases of the liver // materials of the II International Interdisciplinary Forum "Medicine of the liver". M .: Mediabyuro Status presence, 2012. p. 27—31.
- Figueroa JD, et al. Standardized measures of lobular involution and subsequent breast cancer risk among women with benign breast disease: a nested case-control study. Breast Cancer Research & Treatment 2016;159(1):163-172.
- Musina E.V., Kogan I.Yu. Possibilities of using biguanides in fibrocystic disease in women of reproductive age // Journal of Obstetrics and Women’s Diseases. - 2019. - T. 68. - No. 3. - S. 35 - 40.Silvera SAN, Rohan TE. Benign proliferative epithelial disorders of the breast: a review of the epidemiologic evidence. Breast Cancer Research and Treatment. 2007;110(3):397 - 409.
- Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123.
- Gonzalez - Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010;16(6):1695-1700.
- Boyd DB. Insulin and Cancer. Integr Cancer Ther. 2016;2(4): 315-329.
- Tarique M. A Prospective Study on Prevalence of Hyperprolactinemia & Hypothyroidism in Benign Breast Diseases. Int Arch BioMed Clin Res. 2019;5(1):18.
- Gunter MJ, et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 2009;101:48—60. Abstract/FREE Full TextGoogle Scholar.
- Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579-591.
- Catsburg C., Gunter M.J., Chen C. et al. Insulin, estrogen, inflammatory markers, and risk of benign proliferative breast disease. Cancer Res 2014;74(12):3248—58.
- Chelsea Catsburg, Marc J. Gunter, et al. Insulin, Estrogen, Inflammatory Markers, and Risk of Benign Proliferative Breast Disease Cancer Res; 74(12) June 15, 2014 DOI: 10.1158/0008-5472.CAN-13-3514.
- Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647.
- Dowling RJ, Niraula S, Stambolic V, Goodwin PJ. Metformin in cancer: translational challenges. J Mol Endocrinol. 2012;48(3):R31- 43.
- Heckman - Stoddard BM, DeCensi A, Sahasrabuddhe VV, Ford LG. Repurposing metformin for the prevention of cancer and cancer recurrence. Diabetologia. 2017;60(9):1639-1647.
- Tu C, Ren X, He J, Zhang C, Chen R, Wang W, Li Z. The Value of LncRNA BCAR4 as a Prognostic Biomarker on Clinical Outcomes in Human Cancers. J Cancer. 2019;10(24):5992-6002. [PMC free article] [PubMed].
- Sonia Del Barco Metformin: Multi-faceted protection against cancer Oncotarget 2011; 2: 896 — 917.
